Hansoh Pharmaceutical's commendable ROE, impressive earnings growth, and profit reinvestment strategy signal positive performance. Future payout ratio is pegged around 22% and ROE about 12%. Analysts foresee gain in the company's earnings.
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more